UNSPSC 51111803: Estramustine

This classification denotes a tubulin binding agent and nitrogen mustard compound with the molecular formula C23H31Cl2NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 35LT29625A, chemically known as 17-hydroxyestra-1,3,5(10)-trien-3-yl bis(2-chloroethyl)carbamate but generally known as estramustine, which bears US NIH Compound Identifier 18140. European Medicines Agency schedules Estramustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07246MIG.

UNSPSC 51111803 Estramustine is a Commodity code covering a single pharmaceutical product — estramustine phosphate sodium, an oral chemotherapy agent used primarily in prostate cancer treatment. State and local governments procure this drug through health departments, prison systems, and public hospital networks for inmate and indigent patient populations. The drug is purchased as a finished pharmaceutical product, typically in tablet or capsule form, through standing orders or competitive bid cycles aligned with formulary reviews and annual budget cycles.

The recent-opportunities block contains no entries for this code, indicating no active state or local solicitations are currently posted or have been posted recently. Without current market activity to characterize, issuing-body mix, geographic spread, and recent representative opportunities cannot be identified from available sources. This absence of recent procurement signals suggests either limited demand, established vendor relationships that do not trigger new bids, or formulary decisions that have shifted purchasing to alternative agents.